Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double‐blind randomized clinical trial DOI Open Access
Baltazar Dias Sanabria, Hélio Amante Miot, Rodney Sinclair

et al.

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

Low-dose oral minoxidil (OM) is effective for male androgenetic alopecia (AGA).1, 2 Sublingual (SM) was proposed as an alternative to minimize adverse systemic cardiovascular effects and increase clinical response by bypassing the hepatic first-pass metabolism improving bioavailability.3 Bypassing would reduce rate of rise circulating activated drug its vascular effect. However, efficacy tolerability have yet be compared OM.4 This double-blind, randomized trial compares efficacy, safety SM 5 mg per day versus OM daily 24 weeks in patients with AGA. Men AGA (Norwood-Hamilton 3 V, 4 V V) were (1:1) into two groups: placebo once a or sublingual weeks. The primary outcome change total hair density vertex region (TrichoLab® H2H-matching technology).5 Secondary outcomes included changes non-vellus photographic evaluations. One hundred ten participants enrolled specialized clinic Brazil (Table 1). Eighty-five completed study; 43 SL group, 42 group. increased 24.5 hairs/cm2 (95% CI: 18.8–30.2) group 21.8 14.9–29.0) Non-vellus 7.8 4.2–11.4) 7.4 (95%CI: mean from baseline greater but this difference not statistically significant (p > 0.5). According consensus three treatment-blind dermatologists, 42% 40% showed improvement vertex, no between groups = 0.69) 2). Hypertrichosis main event reported. Palpitation less frequent (0% vs. 9%; p 0.048). Minoxidil pro-drug, order act, it must bio-activated sulfate.6 Considerable inter-individual variation both follicular sulfotransferase activity may explain among patients.7-9 In previous 40 AGA, proven safe at doses 0.45, 1.35 4.05 day.4 No described. study, different administration methods did impact improvement. there frequency palpitations. vasodilation caused can lead reflex tachycardia, commonly reported few hours after ingestion. using low-dose (0.25–5 daily) loss, palpitations been described up 4% cases.10 absence could explained escaping immediate liver activation. Maybe other events like hypertrichosis, oedema dizziness because they depend on drug's long-term So, impacted short differences. limitations our study include single-centre design, blood pressure heart monitoring, small sample size. conclusion, demonstrate superiority over treatment Both treatments well tolerated, palpitation principal investigator had full access all data takes responsibility integrity accuracy analysis. None. BS, CC, PMR HAM: RS: patents: loss (telogen effluvium); treat excessive shedding; US10226462, us16344288, us201990269684, us162522107; Stock owner: Samson Clinical Pty Ltd. protocol approved Ethics Committee Anhaguera—UNIDERP (# 5.936.863). Consent publication recognizable patient photographs identifiable material obtained authors time article submission journal, stating that gave consent understanding information publicly available. RBR-7wsgdm8. support findings are available corresponding author upon reasonable request.

Language: Английский

Hair Longevity—Evidence for a Multifactorial Holistic Approach to Managing Hair Aging Changes DOI Open Access
Gillian E. Westgate,

Daniela Grohmann,

Manuel Sáez Moya

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1894 - 1894

Published: March 11, 2025

Loss of hair density—hair thinning and balding— is typically referred to as male female pattern alopecia. Causes include genetic predisposition links the impact dihydrotestosterone on follicle dermal papilla, which are characterized by an increase in number vellus follicles. Links chronological aging unclear. Proven treatments remain few still targeting tested those experiencing classical loss. The way changes with aging, especially women, can be considered having a much broader scope. Trends managing density, length, fiber quality now mostly cocktail approaches—whether topical, injected, or oral—recognizing that solutions more likely require multifactorial strategy. This review examines evidence for holistic approach addressing unwanted loss, includes nutrition, lifestyle, stress management, scalp care, well co-morbidities other health concerns. We discuss strengths limitations clinical study design investigate efficacy using approaches. propose this strategy will contribute emerging concept longevity follicle, scalp, targeted maintaining anagen most appropriate route achieving healthy aging. Finally, we problem facing patients consumers regarding quantity misinformation how it influences choosing from fast-growing market bypass pharmaceutical thinning.

Language: Английский

Citations

0
Evaluation of morphological and cytotoxic effects of minoxidil on Phaseolus vulgaris L. as a plant model DOI
Seir Antonio Salazar Mercado,

Cristobal Zambrano Parada

Environmental Science and Pollution Research, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 16, 2024

Language: Английский

Citations

2
Genomic Markers and Personalized Medicine in Androgenetic Alopecia: A Comprehensive Review DOI Creative Commons
Laura Vila, Valentina Russo, Gustavo Torres de Souza

et al.

Cosmetics, Journal Year: 2024, Volume and Issue: 11(5), P. 148 - 148

Published: Aug. 27, 2024

Androgenetic alopecia (AGA) is the most common form of hair loss, significantly affecting both men and women worldwide. Characterized by progressive thinning AGA primarily mediated dihydrotestosterone (DHT). Recent research has identified numerous single-nucleotide polymorphisms (SNPs) associated with AGA, particularly in genes involved androgen metabolism, prostaglandin pathways, vasodilation. These genetic markers offer insights into pathophysiology potential therapeutic targets. Pharmacogenetics, study how variations influence drug response, holds promise for personalized treatment. Identifying SNPs that affect efficacy treatments like minoxidil finasteride enables development tailored strategies. For instance, variants SRD5A2 gene, which affects DHT can predict responsiveness to 5-alpha-reductase inhibitors. Beyond pharmacogenetics, RNA interference (RNAi) technologies, e.g., small interfering RNAs (siRNAs), present new avenues. Studies have shown RNAi-based targeting receptors, promoting growth models. Integrating pharmacogenetic clinical practice transform management, enhancing treatment patient outcomes. In conclusion, are crucial developing while emerging RNAi technologies promising interventions. advancements represent significant steps toward more effective individualized therapies.

Language: Английский

Citations

1
Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double‐blind randomized clinical trial DOI Open Access
Baltazar Dias Sanabria, Hélio Amante Miot, Rodney Sinclair

et al.

Journal of the European Academy of Dermatology and Venereology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

Low-dose oral minoxidil (OM) is effective for male androgenetic alopecia (AGA).1, 2 Sublingual (SM) was proposed as an alternative to minimize adverse systemic cardiovascular effects and increase clinical response by bypassing the hepatic first-pass metabolism improving bioavailability.3 Bypassing would reduce rate of rise circulating activated drug its vascular effect. However, efficacy tolerability have yet be compared OM.4 This double-blind, randomized trial compares efficacy, safety SM 5 mg per day versus OM daily 24 weeks in patients with AGA. Men AGA (Norwood-Hamilton 3 V, 4 V V) were (1:1) into two groups: placebo once a or sublingual weeks. The primary outcome change total hair density vertex region (TrichoLab® H2H-matching technology).5 Secondary outcomes included changes non-vellus photographic evaluations. One hundred ten participants enrolled specialized clinic Brazil (Table 1). Eighty-five completed study; 43 SL group, 42 group. increased 24.5 hairs/cm2 (95% CI: 18.8–30.2) group 21.8 14.9–29.0) Non-vellus 7.8 4.2–11.4) 7.4 (95%CI: mean from baseline greater but this difference not statistically significant (p > 0.5). According consensus three treatment-blind dermatologists, 42% 40% showed improvement vertex, no between groups = 0.69) 2). Hypertrichosis main event reported. Palpitation less frequent (0% vs. 9%; p 0.048). Minoxidil pro-drug, order act, it must bio-activated sulfate.6 Considerable inter-individual variation both follicular sulfotransferase activity may explain among patients.7-9 In previous 40 AGA, proven safe at doses 0.45, 1.35 4.05 day.4 No described. study, different administration methods did impact improvement. there frequency palpitations. vasodilation caused can lead reflex tachycardia, commonly reported few hours after ingestion. using low-dose (0.25–5 daily) loss, palpitations been described up 4% cases.10 absence could explained escaping immediate liver activation. Maybe other events like hypertrichosis, oedema dizziness because they depend on drug's long-term So, impacted short differences. limitations our study include single-centre design, blood pressure heart monitoring, small sample size. conclusion, demonstrate superiority over treatment Both treatments well tolerated, palpitation principal investigator had full access all data takes responsibility integrity accuracy analysis. None. BS, CC, PMR HAM: RS: patents: loss (telogen effluvium); treat excessive shedding; US10226462, us16344288, us201990269684, us162522107; Stock owner: Samson Clinical Pty Ltd. protocol approved Ethics Committee Anhaguera—UNIDERP (# 5.936.863). Consent publication recognizable patient photographs identifiable material obtained authors time article submission journal, stating that gave consent understanding information publicly available. RBR-7wsgdm8. support findings are available corresponding author upon reasonable request.

Language: Английский

Citations

1